<DOC>
	<DOCNO>NCT02585960</DOCNO>
	<brief_summary>1 . To compare efficacy safety PK-guided treatment BAX 855 target FVIII trough level 1-3 % approximately 10 % ( 8-12 % ) 2 . To characterize pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter BAX 855</brief_summary>
	<brief_title>BAX 855 PK-Guided Dosing</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>INCLUSION CRITERIA : Participants transition another BAX 855 study meet ALL follow criterion eligible study : 1 . Participant complete end study visit BAX 855 study transition ongoing Baxalta Continuation Study 261302 . 2 . Participant either receive ondemand treatment prophylactic treatment BAX 855 Annual Bleed Rate ( ABR ) ≥ 2 document treat past 12 month . 3 . Participant human immunodeficiency virus negative ( HIV ) ; HIV+ stable disease CD4+ count ≥ 200 cells/mm^3 , confirmed central laboratory . 4 . Participant willing able comply requirement protocol . Newly recruit participant ( ie transition another BAX 855 study ) include BAX855 naïve participant meet ALL follow criterion eligible study : 1 . Participant severe hemophilia A ( FVIII clot activity &lt; 1 % ) confirm central laboratory historically document FVIII clot activity perform certified clinical laboratory and/or FVIII gene mutation consistent severe hemophilia A 2 . Participant previously treat plasmaderived FVIII concentrate recombinant FVIII ≥ 150 documented exposure day ( EDs ) 3 . Participant either receive ondemand treatment prophylactic treatment annual bleeding rate ≥ 2 document treat past 12 month . 4 . Participant Karnofsky performance score ≥ 60 screen 5 . Participant HIV ; HIV+ stable disease CD4+ count ≥ 200 cells/mm^3 , confirmed central laboratory screen 6 . Participant hepatitis C virus negative ( HCV ) antibody ( positive , additional PCR testing performed ) , confirmed central laboratory screening ; HCV+ chronic stable hepatitis 7 . If female childbearing potential , participant present negative urine pregnancy test agree employ adequate birth control measure duration study 8 . Participant willing able comply requirement protocol . EXCLUSION CRITERIA : Participants transition another BAX 855 study meet ANY follow criterion eligible study : 1 . Participant develop confirm inhibitory antibody FVIII titer ≥ 0.6 BU use Nijmegen modification Bethesda assay determine central laboratory course previous BAX 855 study . 2 . Participant diagnose acquire hemostatic defect hemophilia A . 3 . The participant 's weight &lt; 35 kg &gt; 100 kg . 4 . Participant 's platelet count &lt; 100,000/mL . 5 . Participant abnormal renal function ( serum creatinine &gt; 1.5 time upper limit normal ) . 6 . Participant active hepatic disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥ 5 time upper limit normal . 7 . Participant schedule receive systemic immunomodulating drug ( e.g . corticosteroid agent dose equivalent hydrocortisone great 10 mg/day , αinterferon ) antiretroviral chemotherapy study . 8 . Participant clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect participant 's safety compliance . 9 . Participant plan take part clinical study course study . 10 . Participant member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study . Newly recruit participant ( ie transition another BAX 855 study ) meet ANY follow criterion eligible study : 1 . Participant detectable FVIII inhibitory antibody ( ≥ 0.6 BU use Nijmegen modification Bethesda assay ) confirm central laboratory screening . 2 . Participant history confirm FVIII inhibitor titer ≥ 0.6 Bethesda Units ( BU ) ( determine Nijmegen modification Bethesda assay assay employ respective cutoff local laboratory ) time prior screening . 3 . Participant diagnose inherit acquire hemostatic defect hemophilia A ( eg , qualitative platelet defect von Willebrand 's disease ) . 4 . The participant 's weight &lt; 35 kg &gt; 100 kg . 5 . Participant 's platelet count &lt; 100,000/mL . 6 . Participant know hypersensitivity towards mouse hamster protein , PEG Tween 80 . 7 . Participant severe chronic hepatic dysfunction [ eg , ≥ 5 time upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , confirmed central laboratory screening , document INR &gt; 1.5 ] . 8 . Participant severe renal impairment ( serum creatinine &gt; 1.5 time upper limit normal ) . 9 . Participant current recent ( &lt; 30 day ) use pegylated drug prior study participation schedule use drug study participation . 10 . Participant schedule receive course study , systemic immunomodulating drug ( e.g . corticosteroid agent dose equivalent hydrocortisone great 10 mg/day , αinterferon ) antiretroviral chemotherapy . 11 . Participant participate another clinical study involve IP investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . 12 . Participant medical , psychiatric , cognitive illness recreational drug/alcohol use , opinion investigator , would affect participant safety compliance . 13 . Participant member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>